Repugnant Economics – Marginal REVOLUTION


I spoke on a panel at AEI with Nobelist Al Roth about his new book, Moral Economics, which covers “repugnant markets,” from prostitution to surrogacy to kidney exchange. A fun book!

My case study was acting. Acting was considered repugnant for over 2,000 years. In Rome, actors could not vote, hold office, or be trusted to give an oath in legal proceedings. So why don’t we find acting repugnant today?

One lesson: weighing costs and benefits is not enough. Roth discusses empirical research showing that legalizing prostitution cut STDs and sexual assaults—against prostitutes and others. But evidence alone won’t shift a repugnance norm. You also have to reframe the activity. Acting, for example was reframed from body rental to a skill requiring intelligence, training and ability. So I went out of my way to say that I am a fan of Aella—though not her only fan—and that I see no reason why escorting should not be considered a skill, requiring intelligence, training, and ability. I can think of few better ways of raising social welfare than making sex 10% better!

I also spoke on human challenge trials. Roth and I agree: challenge trials could have sped up COVID vaccines and saved tens of thousands of lives. We should be angry this didn’t happen. Why didn’t it? Even though most people think human challenge trials are a good idea, there was a repugnance bottleneck because the minority who did find human challenge trials repugnant were in charge. I discuss how to change this.

Al leads the discussion. My comments start at 25:15.




Source link

  • Related Posts

    American Doctor Tests Positive for Ebola While Working in Congo

    IE 11 is not supported. For an optimal experience visit our site on another browser. Ex-Assistant Principal Faces Trial Over Teacher Shot by 6‑Year‑Old 01:46 LIRR Service to Resume After…

    Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease

    About Risen (Shanghai) Pharma Tech Co., Ltd.Risen Pharma is an internationally competitive clinical-stage biotech company focusing on developing and commercializing highly-needed, patient-accessible therapeutics. The company’s integrated capabilities cover all stages…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Jaxon Smith-Njigba points out glaring mistake on offensive player of the year award: ‘It’s getting disrespectful’

    Jaxon Smith-Njigba points out glaring mistake on offensive player of the year award: ‘It’s getting disrespectful’

    Grayson Perry’s life story to be told in ‘outrageous’ musical | Stage

    Grayson Perry’s life story to be told in ‘outrageous’ musical | Stage

    20 More Widebodies: Lufthansa Doubles Down On Boeing 787-9 and Airbus A350-900

    20 More Widebodies: Lufthansa Doubles Down On Boeing 787-9 and Airbus A350-900

    American Doctor Tests Positive for Ebola While Working in Congo

    American Doctor Tests Positive for Ebola While Working in Congo

    The Download: Musk v. Altman, smart glasses for warfare, and Google I/O

    The Download: Musk v. Altman, smart glasses for warfare, and Google I/O

    Defence minister visiting Snowbirds base amid speculation over team’s future

    Defence minister visiting Snowbirds base amid speculation over team’s future